Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Optimer Pharmaceuticals, Inc.

http://www.optimerpharma.com/

Latest From Optimer Pharmaceuticals, Inc.

Finance Watch: Clouds Still Darken Biopharma Sector Despite Sunny Forecasts

Restructuring Edition: The industry emerged from the J.P. Morgan Healthcare Conference feeling renewed confidence about deal-making and financing, but drug developers continue to run short on cash or cut programs and jobs before the money runs out, including Cara, PMV and Ikena.

Financing Restructuring

Finance Watch: Kyverna, Alto Offerings Could Land In IPO Investors’ Sweet Spot

Public Company Edition: Kyverna and Alto Neuroscience, which may go public in the US this year, have drug candidates in or nearing mid-stage trials. Also, Zealand’s private placement raises $211.4m, Praxis prices a $150m offering and Solid grosses $108.9m in stock sale.

Financing Growth

Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact

Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.

Deal Watch Business Strategies

Roche Signs Up Medilink As China Biotech ADC Deal Spree Continues

The Swiss drug maker teams up with Chinese biotech Medilink to gain access to a preclinical c-Met-targeting antibody-drug conjugate and potential competitor to two frontrunners from AbbVie.

China Deals
See All

Company Information

UsernamePublicRestriction

Register